A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases

Accurate identification of intermediate risk (Gleason 3 + 4 = 7) prostate cancer patients with low risk of disease progression is an unmet challenge in treatment decision making. Here we describe a gene signature that could guide clinicians in the selection of patients with intermediate stage clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Chee W, Maxwell, Pamela, Alvi, Muhammad A, McQuaid, Stephen, Waugh, David, Mills, Ian, Salto‐Tellez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903700/
https://www.ncbi.nlm.nih.gov/pubmed/29665325
http://dx.doi.org/10.1002/cjp2.94

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903700/
https://www.ncbi.nlm.nih.gov/pubmed/29665325
http://dx.doi.org/10.1002/cjp2.94

Ejemplares similares